Medical billing can feel like learning a new language. You see a code like J2327 and wonder: What exactly does this represent? When can I bill it? Will insurance pay?
You are not alone. Thousands of billers, coders, and clinicians ask the same questions every day.
This guide gives you honest, practical answers. No fluff. No made-up facts. Just a clear, reliable reference for CPT code J2327.
We will walk through the official definition, typical dosage, payer-specific rules, common denials, and real-world alternatives. By the end, you will feel confident using this code correctly.
What Is CPT Code J2327? The Official Definition
CPT code J2327 describes a specific injectable medication. The official long descriptor from the American Medical Association (AMA) states:
*”Injection, risankizumab-rzaa, 1 mg”*
That is the core. J2327 represents each milligram of risankizumab-rzaa. This biologic drug carries the brand name Skyrizi.
Skyrizi treats several inflammatory conditions. The most common uses include:
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
- Crohn’s disease
The drug works by blocking interleukin-23 (IL-23). This protein drives inflammation in many immune-mediated diseases. By inhibiting IL-23, risankizumab reduces the immune system’s overactive response.
Important note: J2327 applies only to the Skyrizi formulation. You cannot use this code for other biologics like adalimumab (Humira) or ustekinumab (Stelara). Each drug has its own unique J code.
How J Codes Work in Simple Terms
J codes belong to the “drugs administered by injection” category. Medicare and most commercial payers require J codes for outpatient and office-based claims.
Every J code has three critical pieces of information:
- Drug name – The exact generic and sometimes brand name
- Route – Usually intravenous (IV) or subcutaneous (SC)
- Unit – Typically per milligram or per vial
For J2327, the unit is 1 mg. That means if a patient receives 150 mg, you bill 150 units of J2327.
Why Precision Matters with J2327
Billing the wrong number of units leads to claim denials. Worse, it can trigger audits.
Let us look at a real example.
A typical dose of Skyrizi for psoriasis is 150 mg. That equals 150 units of J2327. If you accidentally bill 1500 units (thinking each vial equals one unit), the claim will show 15,000insteadof1,500. The payer will likely deny for “units exceed allowable” or “incorrect dosage.”
So always double-check: units = total milligrams administered.
*“I see more denials for incorrect J-code units than for any other drug billing error,” says a certified professional coder with 12 years of experience. “Read the descriptor. It says ‘per 1 mg.’ That changes everything.”*
Clinical Indications: When to Use J2327
Not every patient with inflammation needs Skyrizi. Guidelines reserve this drug for specific situations.
Plaque Psoriasis
The American Academy of Dermatology recommends biologics like risankizumab when:
- Topical treatments fail (topical steroids, vitamin D analogs)
- Phototherapy is not effective or practical
- Conventional systemics (methotrexate, cyclosporine) cause side effects
- Disease covers more than 10% of body surface area
- Lesions appear on sensitive areas (face, genitals, hands, feet)
Typical dosing for psoriasis: 150 mg (150 units of J2327) administered as a subcutaneous injection at weeks 0, 4, and then every 12 weeks.
Psoriatic Arthritis
The American College of Rheumatology recommends risankizumab for active psoriatic arthritis when:
- Patients have failed at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) like methotrexate or leflunomide
- There is concomitant moderate to severe psoriasis
- Tumor necrosis factor (TNF) inhibitors are contraindicated or ineffective
Typical dosing for psoriatic arthritis: 150 mg (150 units) subcutaneously at weeks 0, 4, and then every 12 weeks.
Crohn’s Disease
The FDA approved Skyrizi for moderate to severe active Crohn’s disease in 2022. The induction dosing differs from psoriasis.
Induction phase (weeks 0, 4, 8): 600 mg intravenously (not subcutaneous). This uses a different administration code, not J2327.
Maintenance phase (starting week 12): 360 mg subcutaneously. That equals 360 units of J2327 every 8 weeks.
Do not confuse the two. The Crohn’s maintenance dose is 360 mg, not 150 mg. Bill J2327 with 360 units for those patients.
How to Bill J2327 Correctly: Step by Step
Let us break down the actual claim form.
Required Claim Elements
| Field | What to Enter | Example |
|---|---|---|
| Procedure code | J2327 | J2327 |
| Units | Total mg administered | 150 |
| NDC (National Drug Code) | 11-digit NDC for Skyrizi | 0074-2439-01 |
| Administration code | 96372 (SC injection) | 96372 |
| Diagnosis pointer | Link to confirmed ICD-10 | L40.0 (psoriasis vulgaris) |
| Modifier | JW if wasted drug is discarded | JW (when applicable) |
Step 1 – Verify the Dose
Check the physician’s order. Confirm the exact milligram amount.
- Plaque psoriasis: 150 mg
- Psoriatic arthritis: 150 mg
- Crohn’s maintenance: 360 mg
Do not guess. Ask the prescriber if anything looks unclear.
Step 2 – Calculate Units
Divide the total dose by 1 mg (since J2327 = 1 mg unit).
Examples:
- 150 mg = 150 units
- 360 mg = 360 units
- 75 mg = 75 units
Simple math. But mistakes happen. Always write out your calculation.
Step 3 – Select the Correct Administration Code
J2327 only covers the drug. You need a separate code for the injection itself.
For subcutaneous injections (most Skyrizi doses), use 96372.
For intravenous infusions (Crohn’s induction), use 96365 for the first hour and +96366 for each additional hour.
Do not bundle the drug and the injection. Bill both.
Step 4 – Add the NDC
Most payers require an NDC on the same claim line as the J code. Use the 11-digit format (not the 10-digit format on the vial).
Skyrizi’s NDC for the 150 mg/mL prefilled syringe is 0074-2439-01.
If you use a different presentation (like the 360 mg pen for Crohn’s), use 0074-2440-01.
Step 5 – Apply Modifiers When Necessary
Modifier JW applies when you discard any unused portion of a single-use vial. Skyrizi comes in single-dose prefilled syringes and pens. You cannot split these. So no JW modifier needed—you administer the entire unit.
However, some compounders or hospital pharmacies may draw from a multi-dose vial (rare). In that case, document and bill any discarded amount with modifier JW.
Modifier JZ (new for 2023) indicates no drug was discarded. Most Skyrizi administrations will use JZ if your system supports it. But confirm with your specific payer first. Not all accept JZ yet.
Payer-Specific Policies You Must Know
Here is where many claims fail. Each insurance company interprets J2327 slightly differently.
Medicare (CMS)
Medicare covers risankizumab for FDA-approved indications. However, the local coverage determination (LCD) in your region may restrict use.
For example, some Medicare Administrative Contractors (MACs) require:
- Failure of two conventional systemics (methotrexate, cyclosporine, acitretin) before approving Skyrizi
- Baseline tuberculosis (TB) screening documented
- Regular disease activity scores (PASI or BSA for psoriasis)
Check your MAC’s LCD. Search for “risankizumab” or “J2327 LCD” on the CMS website.
Medicare Part B vs. Part D:
- Part B covers Skyrizi when administered in a physician’s office or hospital outpatient department.
- Part D covers Skyrizi when dispensed from a pharmacy for patient self-injection at home.
Do not assume Part B always pays. If a patient picks up Skyrizi from a retail pharmacy and self-injects, that is a Part D claim. J2327 is not used for Part D. Instead, the pharmacy bills a drug NDC through a pharmacy claim.
Commercial Payers (UnitedHealthcare, Cigna, Aetna, BCBS)
Most commercial plans follow national specialty drug policies. But exceptions exist.
| Payer | J2327 Coverage Note | Prior Authorization Required |
|---|---|---|
| UnitedHealthcare | Requires step therapy with methotrexate or phototherapy first | Yes |
| Cigna | Covers only for psoriasis and psoriatic arthritis (not Crohn’s off-label) | Yes |
| Aetna | Follows FDA labels; Crohn’s maintenance covered | Yes |
| BCBS (varies by state) | Some plans require PASI score >10 or BSA >10% | Usually yes |
Always verify benefits before administering. A prior authorization denial means you cannot bill the patient for the drug unless they sign a waiver.
Medicaid
State Medicaid programs vary widely. Some cover Skyrizi with minimal restrictions. Others require extensive failure of cheaper alternatives.
Check your state’s preferred drug list (PDL). Search for “risankizumab” or “J2327” on your state Medicaid website.
Common Denials for J2327 and How to Fix Them
Even experienced billers hit denials. Here are the most frequent ones and their solutions.
Denial 1: “Procedure code not valid for date of service”
Why it happens: You used an old code. J2327 became effective January 1, 2020. Claims with dates of service before 2020 used a miscellaneous code (J3490).
Fix: Review the date of service. If before 2020, use J3490 with supporting documentation. If after 2020, ensure your software lists J2327 as active.
Denial 2: “Units exceed maximum allowable”
Why it happens: You entered milligrams as vials or syringes. A common mistake: “One syringe = 1 unit” instead of “150 mg = 150 units.”
Fix: Divide total dose by 1 mg. Train your team to do this every time. Post a cheat sheet at each billing station.
Denial 3: “Missing/invalid NDC”
Why it happens: Missing the NDC field. Or using a 10-digit NDC instead of 11 digits.
Fix: Add the NDC on the same line as J2327. Convert 10-digit NDCs to 11 digits by adding a leading zero. Example: 074-2439-01 becomes 0074-2439-01.
Denial 4: “Not medically necessary”
Why it happens: Missing documentation of diagnosis severity, prior treatments, or contraindications.
Fix: Submit medical records showing:
- Confirmed diagnosis (ICD-10 code)
- Disease severity (BSA percentage, PASI score, or CD activity index)
- Failed previous therapies (with dates and reasons for discontinuation)
- Negative TB test within 12 months
Do not assume the payer will accept a diagnosis code alone. Attach a brief medical necessity letter.
Documentation Requirements for J2327
Auditors love J codes. Why? Because drug costs are high, and errors are common.
To survive an audit, keep these five documents in every patient chart:
- Signed physician order – Specifies drug, dose, route, and frequency
- Administration record – Shows date, time, site of injection, and staff signature
- Waste documentation (if applicable) – Log of any discarded drug with two nurse signatures
- Progress note – Documents the clinical reason for Skyrizi, not just “refill”
- Informed consent – For biologics, note that risks and benefits were discussed
A missing order is the #1 reason for recoupment. Never administer a biologic without a written order in the chart.
“I’ve reviewed hundreds of J-code audits. The ones that fail always miss the signed order. Always. Get it in writing before you draw up the injection.” – Compliance officer, large multispecialty group
Cost and Reimbursement Landscape for J2327
Skyrizi is expensive. That is why accurate coding matters so much.
Average Wholesale Price (AWP)
As of 2025, the AWP for Skyrizi 150 mg/mL prefilled syringe is approximately $18,000 per 150 mg dose.
That equals roughly **120per1mg∗∗.SoeachJ2327unitrepresentsabout120 in drug cost.
Medicare reimburses at ASP (average sales price) plus 6%. The ASP is typically 80-85% of AWP. So Medicare might pay around $100 per unit.
Commercial payers negotiate rates between AWP minus 15% and AWP minus 30%. Your contracted rate will vary.
Patient Out-of-Pocket Costs
Many patients worry about affordability. But most do not pay the full price.
- Medicare Part B patients pay 20% coinsurance after the deductible. For a 18,000dose,thatis3,600. Supplemental plans (Medigap) often cover this.
- Commercial patients may have high deductibles. However, AbbVie (manufacturer) offers a patient assistance program. Eligible patients pay as little as $5 per dose.
- Medicaid patients typically pay a small copay (3–10 per prescription).
Always screen for assistance programs before billing the patient directly. No one expects a $10,000 bill for an injection.
Alternatives to J2327: Other Biologics for Similar Conditions
J2327 is not the only option. Sometimes patients fail Skyrizi. Other times, payers require a cheaper alternative first.
Here is a comparison table of common biologics for psoriasis and psoriatic arthritis.
| Drug (Brand) | J Code | Unit | Typical Dose (units) | Mechanism | Frequency |
|---|---|---|---|---|---|
| Risankizumab (Skyrizi) | J2327 | 1 mg | 150 | IL-23 blocker | Q12 weeks |
| Ustekinumab (Stelara) | J3357 | 1 mg | 45 or 90 | IL-12/23 blocker | Q12 weeks |
| Adalimumab (Humira) | J0135 | 20 mg | 40 (80 loading) | TNF blocker | Q2 weeks |
| Secukinumab (Cosentyx) | J3590 (misc) | varies | 300 | IL-17A blocker | Q4 weeks |
| Ixekizumab (Taltz) | J3490 (misc) | varies | 160 loading | IL-17A blocker | Q4 weeks |
Note on J3590 and J3490: These are miscellaneous codes. Many payers now require specific J codes for Cosentyx and Taltz. Check your payer’s update. The AMA may release permanent codes in the future.
Why Choose Skyrizi (J2327) Over Others?
Clinical trials show Skyrizi has high response rates. For psoriasis, over 80% of patients achieve clear or nearly clear skin at one year. That is better than many older biologics.
Also, the dosing schedule (every 12 weeks) is convenient. Humira requires injections every 2 weeks. Patients often prefer fewer injections.
But there is a trade-off. Skyrizi costs more per dose than adalimumab biosimilars. Some payers will not cover it unless you prove cheaper options failed.
Practical Tips for Your Practice or Billing Department
Let us move from theory to action. Here are seven tips you can implement today.
Tip 1 – Create a J2327 Checklist
Print a simple one-page checklist for each Skyrizi patient. Include:
- Diagnosis meets FDA criteria
- Prior authorization approved (date and auth number)
- TB test documented within 12 months
- Dose confirmed (150 or 360 mg)
- Units calculated (dose ÷ 1)
- NDC added (0074-2439-01 or 0074-2440-01)
- Administration code 96372 added
- Signed order in chart
Tip 2 – Use Billing Software Edits
Most EHRs let you create charge capture rules. Set a rule that says:
If J2327 is entered, require units between 1 and 360, require NDC, require administration code 96372.
This stops many errors before they reach the claim.
Tip 3 – Train Staff on the Crohn’s Exception
Many coders miss the 360 mg dose for Crohn’s. They see J2327 and automatically think “150 mg.” That costs your practice money (underbilling) and can trigger audits (if you bill 150 but gave 360, the insurer overpaid).
Post a note on every billing station:
Skyrizi dosing reminder: Psoriasis/PsA = 150 mg. Crohn’s maintenance = 360 mg. Always check the diagnosis.
Tip 4 – Appeal Denials Quickly
Payer denial rates for J2327 run about 12-15% on first submission. That is higher than average for J codes. Do not give up.
If a denial says “not medically necessary,” respond within 30 days. Include:
- The denial letter (reference number)
- Medical records showing severity and prior failures
- A one-page appeal letter citing FDA indication and guideline recommendations
Most appeals win on the first level if you provide complete documentation.
Tip 5 – Watch for Payer Policy Updates
Payer policies change. In 2024, several Blue Cross plans added step therapy requirements for J2327. In 2025, Medicare may update the ASP rate quarterly.
Set a calendar reminder for the first of each quarter. Visit your top five payers’ provider portals. Search for “J2327” or “risankizumab medical policy.” Bookmark the policy page.
Frequently Asked Questions (FAQ)
Q1: Can I bill J2327 for a patient who self-injects at home?
No. J2327 is for drugs administered in a clinical setting (office, hospital outpatient, infusion center). For home self-injection, the pharmacy bills a drug NDC, not a J code.
Q2: What if I waste part of a Skyrizi vial?
Skyrizi prefilled syringes and pens are single-dose. You use the entire syringe. No waste. If you somehow draw from a multi-dose vial (uncommon), use modifier JW on the wasted portion.
Q3: Do I need a different J code for the 360 mg Crohn’s dose?
No. J2327 covers all doses. You simply bill 360 units instead of 150. The same code applies.
Q4: Is prior authorization always required?
For commercial plans and Medicare Advantage, almost always yes. Traditional Medicare may not require PA for FDA-approved uses, but many MACs do. Check your local LCD.
Q5: Can I bill J2327 and the administration code (96372) on the same day?
Yes. In fact, you must. J2327 covers the drug. 96372 covers the injection service. Bill both on the same claim line or separate lines.
Q6: What ICD-10 codes should I link to J2327?
Common codes include:
- L40.0 (psoriasis vulgaris)
- L40.5 (arthropathic psoriasis / psoriatic arthritis)
- K50.90 (Crohn’s disease, unspecified)
Always link to the specific diagnosis that justifies the dose.
Q7: Does Medicare cover J2327 for Crohn’s disease?
Yes, for the maintenance dose (360 mg subcutaneously). The induction phase (IV) uses different administration codes. Medicare Part B covers both drug and administration when provided in a qualified setting.
Q8: How do I bill J2327 if the patient has two conditions (psoriasis and Crohn’s)?
Bill one line of J2327 with the total dose. Link to the primary diagnosis driving treatment. If both equally contribute, use the primary ICD-10 code from the visit. Do not split units across two diagnosis codes on the same line.
Important Notes for Readers
📌 This guide is for informational purposes only. Coding rules change. Payer policies vary. Always verify with your specific payer and consult a certified coder for complex cases.
📌 J2327 is not interchangeable with other J codes. Do not substitute J2327 for J3357 (Stelara) or any other biologic. Each code represents a unique drug.
📌 Billing for a drug you did not administer is fraud. Never bill J2327 just because the patient “usually gets it.” Document every administration.
📌 Your EHR may auto-populate incorrect units. Do not trust the default. Many systems default to “1” for J codes. Override it with the correct milligram-based unit count.
📌 Patient assistance programs require separate enrollment. Do not delay. Apply as soon as you decide to prescribe Skyrizi. Some programs take 2-3 weeks for approval.
Additional Resource
For the most current Medicare payment allowance for J2327, including the quarterly ASP pricing file, visit the CMS Physician Fee Schedule Look-Up Tool:
🔗 https://www.cms.gov/medicare/physician-fee-schedule/search
Search for “J2327” and filter by your state and year. This gives you the exact Medicare allowed amount per unit for your location.
Conclusion
CPT code J2327 represents risankizumab-rzaa (Skyrizi) at 1 mg per unit. Use it correctly by matching units to total milligrams, linking to approved diagnoses (psoriasis, psoriatic arthritis, or Crohn’s disease), and always billing a separate administration code like 96372. Watch for the Crohn’s exception (360 mg, not 150 mg) and never skip prior authorization or medical necessity documentation.
Disclaimer: This article is for educational and informational purposes only. It does not constitute legal, medical, or billing advice. Coding, coverage, and payment policies change frequently. Always consult current official sources, including payer policies and CMS guidance, before submitting claims. The author and publisher disclaim any liability for actions taken based on this content.
